PHPatricia Harkins

Patricia Harkins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Patricia Harkins has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prognostic value of quantifying vascular inflammation through ultrasound in patients with giant cell arteritis: the MAGiCUS study

    by Juan Molina-Collada, Sharon Cowley, Colm Kirby, David Kane, Patricia Harkins, Richard Conway, Isabel Castrejón, José María Álvaro-Gracia, Cristina Ponte, Sara Monti, et al.

    Objectives: To assess the prognostic value of ultrasound-based quantification of vascular inflammation for predicting relapses in giant cell arteritis (GCA). Methods: The Monitoring Activity of GCA through UltraSound (MAGiCUS) project is an international, multicentre, prospective, observational study including newly diagnosed GCA patients. Ultrasound of temporal and axillary arteries was conducted at baseline, 1, 3, 6, and 12 months. Vascular inflammation was quantified using the OMERACT GCA Ultrasonographic Score (OGUS). The primary outcome was the occurrence of the first clinical relapse between 6 and 12 months. Results: Among 156 GCA patients from 19 centres, 31 (19.9%) experienced a relapse. In patients without a relapse, OGUS was significantly lower at all follow-up visits than baseline (-0.15 to -0.35). Baseline OGUS was significantly higher in relapsing patients (1.58 vs 1.16, p < 0.001). In multivariate analysis, an increase in 0.1 units in baseline OGUS was associated with relapse (OR 1.19, 95% CI 1.08, 1.34). This association remained significant for 0.1 increases in OGUS at 1 month (OR 1.37, 95% CI 1.17, 1.66) and at 3 months (OR 1.51, 95% CI 1.20, 1.98). The areas under the receiver operating characteristic curve for predicting relapse were 0.70 (95% CI 0.58 –0.80) for baseline OGUS, 0.74 (95% CI 0.60 –0.85) at 1 month, and 0.67 (95% CI 0.56 –0.78) at 3 months. Conclusion: Ultrasound-based quantification of vascular inflammation has prognostic value for predicting relapses during follow-up in GCA. Higher baseline, 1-month and 3-months OGUS are associated with an increased probability of clinical relapse.

  • Open Access

    Elevated levels of serum angiopoietin-1, IL-17, osteopontin and CXCL-9 as markers of vascular inflammation in newly diagnosed PMR

    by Sharon Cowley, Patricia Harkins, Thomas J Butler, Colm Kirby, Danielle Molloy, Richard Conway, David Kane

    Objectives: GCA and PMR are commonly overlapping diseases. Biomarkers for detecting vascular inflammation in PMR patients are lacking. We aimed to determine the diagnostic value of serum levels of angiopoietin-1, angiopoietin-2, interleukin-6, interleukin-17A, interleukin-23, CXCL-9 and osteopontin (OPN) in identifying vascular inflammation in PMR. Methods: This was a multicentre prospective longitudinal study at Tallaght University Hospital (TUH) and St James Hospital (SJH), Dublin recruiting consecutive new patients. Serum levels of biomarkers were measured using the BioTechne ELISA assay kits following manufacturer protocols. Patients had standardized vascular ultrasound (US) of bilateral temporal and axillary arteries to identify vascular inflammation. Results: Samples were collected from 53 PMR, 13 subclinical GCA in PMR (sGCA) and 59 GCA patients. GCA serum was significantly different from PMR; with higher levels of angiopoietin-1 (P < 0.001), angiopoietin-2 (P < 0.001), CXCL-9 (P < 0.001), osteopontin (P < 0.001), IL-6 (P = 0.02) and IL-17 (P < 0.001). Angiopoietin-1, IL-17, osteopontin (P < 0.001) and CXCL-9 (P = 0.004) were all significantly elevated in sGCA in PMR compared with pure PMR at baseline. IL-23, angiopoietin-2 or IL-6 was not significantly different in sGCA in PMR compared with pure PMR. ROC analysis produced AUC of 0.801 for angiopoietin-1 (sensitivity 84.6; specificity 70%), 0.892 for IL-17 (sensitivity 84.6%; specificity 79.2), 0.814 for osteopontin (sensitivity 84.5%; specificity 79.2%) and 0.892 for CXCL-9 (sensitivity 92.3%; specificity 62.3%). Conclusion: sGCA in PMR has a biomarker signature that more closely resembles GCA than PMR. Baseline levels of angiopoietin-1, IL-17, osteopontin and CXCL-9 may help identify PMR patients with vascular inflammation. These may be a useful screening tool to identify PMR patients that would benefit from further work-up.

  • Open Access

    Current Insights and Future Perspectives for the Use of Serological Biomarkers in Polymyalgia Rheumatica

    by Patricia Harkins, Sharon Cowley, Richard Conway

    There is currently no gold standard diagnostic test or validated serological biomarker to monitor disease activity or inform disease prognostication in isolated Polymyalgia Rheumatica (PMR). This presents significant challenges as the diagnosis of PMR is often complicated by multiple disease mimics, and the disease course remains highly variable, with no way to predict who will experience multiple disease relapses and high cumulative glucocorticoid burden. Furthermore, with the expansion of the therapeutic armamentarium of PMR, it is evident that our current one size fits all management strategy is no longer sufficient. In this narrative review, we summarise recent studies evaluating serological biomarkers for the diagnosis and prognostication of PMR, as well as their roles in disease activity monitoring and in identifying concomitant giant cell arteritis. We discuss their limitations, and explore barriers to their clinical translation, and finally highlight key directions for future research studies.


  • Open Access

    Modern Management of Isolated Polymyalgia Rheumatica

    by Patricia Harkins, Sharon Cowley, Eoghan Burke, Robert Harrington, Danielle Molloy, David Kane, Richard Conway

    Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disorder affecting those over 50 years of age. It is clinically heterogenous in both presentation and disease trajectory. Diagnostic complexity is heightened by the absence of a gold standard diagnostic test and the broad spectrum of disease mimics, posing challenges even for experienced rheumatologists. The primary goal of treatment is to restore health-related quality of life by achieving sustained symptom control, suppressing systemic inflammation, and minimising treatment-related toxicity. Despite advances in our understanding of PMR, glucocorticoids (GCs) remain the cornerstone of therapy. However, frequent relapses and prolonged treatment courses in many patients result in high cumulative GC exposure with associated adverse effects, which is of particular concern in this older, typically frailer and more vulnerable patient cohort. The urgent need for effective GC-sparing agents has resulted in pivotal developments over the past decade, notably the SAPHYR trial, which supported the US Food and Drug Administration (FDA) approval of sarilumab as the first biologic therapy for refractory PMR. This represents a major shift in the therapeutic landscape, with several biologic agents now under investigation. These advances, however, highlight gaps in the current management, including the need for rapid access pathways and specialist rheumatologist evaluation in all cases of suspected PMR to facilitate an early and accurate diagnosis, stratified treatment approaches and the accurate detection of a coexisting giant cell arteritis. Furthermore, standardised definitions of relapse and remission, alongside structured monitoring protocols, are lacking. This review explores current diagnostic and treatment strategies for isolated PMR. We also highlight unmet needs in PMR management, and discuss future directions aimed at improving outcomes and redefining the care pathway for PMR.


  • Open Access

    The distinct phenotype of subclinical giant cell arteritis in polymyalgia rheumatica: evidence from a PMR fast-track clinic

    by Sharon Cowley, Patricia Harkins, Colm Kirby, Richard Conway, David Kane

  • Open Access

    Understanding Fatigue and Sleep Disturbance in Polymyalgia Rheumatica: Redefining the Patient Experience and Opportunities for Intervention

    by Patricia Harkins, Sebastian E. Sattui

    For years, polymyalgia rheumatica (PMR) has been conceptualized as a condition with a relatively benign disease course typified by bilateral shoulder pain and stiffness that requires a limited glucocorticoid taper in most.1 However, over the past decade, our understanding of PMR, including its immunopathogenesis, heterogeneity in disease course, and effect on patients9 health-related quality of life (HRQOL) and functioning, has dramatically evolved.


  • Comment on: Real-world outcomes of a dedicated fast-track polymyalgia rheumatica clinic: reply

    by Sharon Cowley, Patricia Harkins, Colm Kirby, Danielle Molloy, Richard Conway, David Kane

    Sharon Cowley, Patricia Harkins, Colm Kirby, Danielle Molloy, Richard Conway, David Kane; Comment on: Real-world outcomes of a dedicated fast-track polymya

  • Comment on: Real-world outcomes of a dedicated fast-track polymyalgia rheumatica clinic. Reply

    by Sharon Cowley, Patricia Harkins, Colm Kirby, Danielle Molloy, Richard Conway, David Kane

    Sharon Cowley, Patricia Harkins, Colm Kirby, Danielle Molloy, Richard Conway, David Kane; Comment on: Real-world outcomes of a dedicated fast-track polymya

  • Open Access

    Real-world outcomes of a dedicated fast-track polymyalgia rheumatica clinic

    by Sharon Cowley, Patricia Harkins, Colm Kirby, Richard Conway, David Kane

    Objectives: To examine the clinical impact of a fast-track PMR clinic to enable early diagnosis and treatment, and to define both patient and disease characteristics in newly diagnosed PMR. Methods: Primary care physicians were invited to refer patients with new PMR to our fast-track clinic. Referral criteria included new onset shoulder or pelvic girdle pain and/or stiffness with elevated inflammatory markers in patients over 50 years. All patients were seen within 72 h of referral. Patients with a rheumatology diagnosis of PMR had an US of their temporal and axillary arteries. Results: 172 patients were referred from primary care over 12 months. 39% of patients referred with suspected PMR had an alternative diagnosis for which PMR regimen glucocorticoids was inappropriate. 55% of the non-PMR diagnoses were other inflammatory rheumatological conditions requiring follow-up. Only 20% of patients referred from primary care already on glucocorticoids were commenced on bone protection. PMR patients were comorbid, with a mean of 2.5 other conditions. 75% of PMR patients experienced a glucocorticoid-related adverse event in the first 12 months of treatment. 17% of patients with new PMR had US features of subclinical GCA. Conclusion: The commencement of glucocorticoid therapy should be deferred until after specialist evaluation to enable an accurate clinical diagnosis. A delay in treatment can only realistically be avoided if general practitioners have access to a fast-track PMR clinic. We believe that rheumatologists should consider establishing fast-track PMR clinics and this study provides a strong case for and a template to support this practice innovation.


  • Open Access

    Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib

    by Robert Harrington, Patricia Harkins, Richard Conway

    Janus kinase inhibitors (JAKis) are the most recent new drug class to arrive to the market for rheumatoid arthritis (RA) treatment. While they have proven to be a very effective treatment option, there remains significant concern regarding the risk of cardiovascular events, thrombosis and malignancy, particularly given the findings of the post-marketing ORAL Surveillance study and FDA black box warnings. This article reviews the key findings of the most impactful cohort of studies and registry data since ORAL Surveillance. It also evaluates the role of JAKis in practice and offers guidance on risk stratifying patients and determining their suitability for a JAKi.